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756a Wednesday, February 24, 2010its>6000 anti-human polyclonal, affinity-purified antibodies of which 49 were
identified by MS and 79 were novel. HPA antibodies were available for 82 the
142 proteins but only 43 reacted positively with the ICDs based on immunohis-
tochemistry. We supplement these approaches with 14 proteins identified using
conventional 2-DE. Combining all techniques. Only 14 proteins were common
to the MS data, HPA antibodies and the literature. We can categorize all 273
identified ICD proteins according to their known functions and demonstrate
their functional interactions in a single inter-active relationship according to
their functions: (i) adhesion, anchoring and binding (88); (ii) enzymes (46);
(iii) proteins that maintain the structure and function of the ICDs (35); (iv) myo-
fibrillar (34); (v) channels (32); (vi) ligands and their receptors (18); (vii) cyto-
plasm proteins (6); and (viii) mechanoreceptors (4). We will now extend these
analyses to ICD proteins that change as a result of human heart failure.
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Phosphorylation sites in Cardiac MyBP-C have been predicted at Ser273,282
and 302 but studies in intact tissue have identified 5 phosphorylted sites and
suggested up to 4.6molsPi/mol MyBP-C is present in human heart.
We analysed MyBP-C phosphospecies in human heart myofibrils by phosphate
affinity SDS-PAGE using a non-specific antibody raised against the MyBP-C
peptide 2-14. We observed six bands corresponding to 0, 1P, 2P, 3P, 4P, 5P
phospho-species. Control experiments with pure MyBP-C indicated that the
antibody labelled all phosphospecies equally. The assigned phosphorylation
levels were confirmed by staining western blots with PhosTools phosphopro-
tein stain. This separation permits direct quantitative determination of
MyBP-C phosphospecies without need for calibration.
In donor heart myofibrils the highly phosphorylated species predominated: 0,
753%: 1P, 151%: 2P, 2357%: 3P, 4152%: 4P, 2058% (n=4) from which
total phosphorylation of MyBP-C was calculated to be 3.4molsPi/mol. In fail-
ing heart unphosphorylated MyBP-C predominated (0, 4854%: 1P, 454%:
2P, 2755%: 151%: 3P, 1754%: 4P, 452%, n=4) and calculated total phos-
phorylation was 1.5 molsPi/mol. Total phosphorylation in failing heart myofi-
brils was 44% of donor and in myectomy samples from HCM patients it was
29% of donor, compared with 45 and 40% respectively determined in previous
assays.
We conclude that MyBP-C is highly phosphorylated in vivo with significant
phosphorylation of at least 5 sites and that phosphorylation is dynamic, being
greatly reduced in pathological muscle. Initial tests using antibodies specific
to Ser 273, 282 and 302 show distinct patterns on phosphate affinity SDS-
PAGE indicating varying preferences for the highly phosphorylated species
of MyBP-C in normal and pathological muscle.
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N-terminal domains of cardiac myosin binding protein-C (cMyBP-C) can acti-
vate actomyosin interactions in the absence of Ca2þ and bind to actin in a phos-
phorylation dependent manner. We have previously shown that two N-terminal
domains, C1 and the MyBP-C motif (‘‘M’’) domain, bind specifically to actin
and to thin filaments; however, the sequences or residues that mediate actin
binding have not been identified. The goal of this study was to identify residues
in the M-domain that contribute to actin binding and to investigate whether in-
teractions between the M-domain and actin mediate the activating properties of
cMyBP-C. We therefore used alanine-scanning mutagenesis to target candidate
actin binding sites in the M-domain that bear homology to the actin binding
motifs in other known actin binding proteins and to assess the effects of muta-
tions on the ability of recombinant proteins to bind actin and activate actomy-
osin interactions in motility assays. Results demonstrate that mutation of select
positively-charged amino acids in the M-domain that are homologous to bind-
ing motifs in known actin binding proteins reduced binding of cMyBP-C to
actin. The mutations also reduced or eliminated the activating properties of re-
combinant cMyBP-C in in vitro motility assays. However, mutation of other
positively-charged amino acids did not affect actin binding or protein func-
tional properties. These results indicate that specific residues within the M-do-
main confer actin binding and that interactions with actin contribute to the func-
tional effects of recombinant cMyBP-C N-terminal proteins. Supported by NIH
HL080367 to SPH and a NSF Graduate Research Fellowship to JFS.3935-Plat
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Cardiac myosin binding protein-C (cMyBP-C) mutations are a leading cause of
hypertrophic cardiomyopathy. cMyBP-C has 11 domains, C0 through C10, that
bind sarcomeric proteins, including myosin and actin. A 29 kDN-terminal frag-
ment (C0C1f) of cMyBP-C containing the first two domains C0 and C1 and the
first 15 residues of the conserved MyBP-C motif is cleaved from cMyBP-C fol-
lowing ischemic-reperfusion injury (Sadayappan et al., JMCC 44:S44, 2008).
Expressed C0C1f fragments inhibit actin velocities in the motility assay at
a 2:1 molar ratio to myosin, similar to other N-terminal fragments: C0C3,
C0C2, and C1C2. Interestingly, fragments containing only the C0C1 domains
do not alter velocity, suggesting the additional 15 residues in C0C1f are neces-
sary for inhibition. Adding C0C1 to the motility assay can partially reverse the
C0C3-mediated inhibition of velocity, suggesting C0C1 may compete with
C0C3 for actin binding. cMyBP-C fragments may affect motility by creating
a tether between actin and the flowcell surface. To test this, motility experi-
ments were performed under high ionic strength, saturating MgATP, and in
the absence of methylcellulose, conditions in which most actin filaments dif-
fuse away from the surface due to weak interactions with myosin. In the pres-
ence of C0C2, many actin filaments bound and translocated on the surface, con-
firming this fragment’s tethering capacity. Additionally, in the laser trap we
adhered C0C3 fragments to a bead in the absence of myosin and observed
C0C3 transiently binding to a single actin filament with an ~100 ms attached
lifetime. We also saw evidence that C0C3 may partially unfold under load.
These experiments strongly suggest that N-terminal domains of cMyBP-C con-
taining the MyBP-C motif tether actin filaments and provide one mechanism
for modulating actomyosin motion generation, i.e. by imposing an effective
viscous load within the sarcomere.
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Protein Kinase C (PKC) regulates contractility of cardiac muscle cells by phos-
phorylating multiple thin- and thick- filament based proteins, and plays key
roles in development of cardiovascular pathologies. Myocardial sarcomeres
also contain a third myofilament, titin, which we demonstrate here to also be
phosphorylated by PKC. Titin phosphorylation was observed in skinned myo-
cardial tissues following incubation with PKCa and this effect was exacerbated
~5 fold in the mouse and ~2.5 fold in the pig by preincubation with Protein
Phosphatase 1 (PP1). In vitro phosphorylation of recombinant protein repre-
senting titin’s spring elements shows that PKCa targets the PEVK spring
element. Mass spectrometry in combination with site-directed mutagenesis
identified two highly conserved sites in the PEVK region that are phosphory-
lated by PKCa (S11878 and S12022); when these two sites are mutated to
alanine, phosphorylation is effectively abolished. Mechanical experiments
with murine and porcine skinned LV myocardium revealed that PKCa
significantly increases titin-based passive tension in a sarcomere length (SL)-
dependent fashion. Single molecule force-extension curves show that PKCa
decreases the PEVK persistence length (from 1.20 nm to 0.55 nm), without
altering the contour length, and using a serially-linked wormlike chain
(WLC) model we show that this results in an ~20% increase in titin-based pas-
sive force with a SL dependence that is similar to that measured in skinned
myocardium following PKCa phosphorylation. We conclude that PKC phos-
phorylation of titin is a novel and conserved pathway that links myocardial sig-
naling and myocardial stiffness.
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The giant sarcomeric protein, titin is the primary determinant of myocardial
passive stiffness. In failing human hearts however, it has been proposed that re-
duced myofilament passive tension is due to an altered titin isoform expression
profile1, 2. In this study we set out to directly quantify the tensile strength of titin
molecules isolated from healthy and diseased myocardium.
